|Articles|June 7, 2017

Chesapeake IRB Announces Acquisition of MaGil IRB

Chesapeake IRB-technology-enabled independent institutional review board (IRB) that serves the clinical research industry-has acquired MaGil IRB.

The acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and more staff, broadening its precense for CROs, pharma companes, and biotech companies.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Chesapeake IRB Announces Acquisition of MaGil IRB

Related Content

FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines

Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy

Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data

How Clinical Teams Can Build Real Trust With Patient Advocacy Organizations

Trending on Applied Clinical Trials Online

The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026

The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver

Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data

How Clinical Teams Can Build Real Trust With Patient Advocacy Organizations

ACT Brief: Epilepsy Trial Feasibility and Family Realities, CRO Partnerships and Strategic Value, and Cortisol and GLP-1 Response